(thirdQuint)L-Glutamine Therapy for Sickle Cell Anemia.

 This is a phase II, prospective, randomized, double-blind, placebo-controlled, parallel-group,study to evaluate the safety and efficacy of oral L-glutamine therapy for patients with sickle cell anemia or sickle IS-thalassemia who are at least 18 years old with focus on the aspect of exercise endurance.

 In this study, the patients will orally take L-glutamine or placebo twice daily, and clinical and hematological parameters will be monitored.

 The adverse events,especially those attributable to L-glutamine therapy, will also be monitored.

 The data obtained will be essential in understanding the role of L-glutamine in therapy for sickle cell anemia and sickle B-thalassemia.

.

 L-Glutamine Therapy for Sickle Cell Anemia@highlight

To primary purpose is to evaluate the effect of L-glutamine therapy on exercise endurance and breath by breath exercise response of sickle cell anemia patients The secondary purpose is to assess the effect of L-glutamine on pain; energy and appetite levels; narcotics usage; and hospital and emergency room visits for sickle cell pain